Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...

Bio-Techne rallied for a third straight day on Thursday, surging 20.08 percent to close at $70.70 apiece, as investors ...

Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.

The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said. Merck KGaA has agreed to buy Bio-Techne for $11.3 billion ...

Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life ...

By Christy Santhosh, Padmanabhan Ananthan and Bhanvi Satija June 25 (Reuters) - German drugmaker Merck KGaA said on Thursday ...

Bio-Techne stock jumps, with Germany’s Merck KGaA buying the company at a 24% premium.

The major stock indexes were mixed on Thursday as slumping mega-cap tech stocks offset a chip stock rally revived by Micron's ...

In the past year, Merck KGaA has turned its attention to growing its business in supplies for the life sciences industry. The ...

Merck’s $11.3B Bio‑Techne deal spotlights life sciences tools stocks. Check top 10 quant-rated healthcare stocks ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the ...